share_log

Novo-Nordisk A/S | 6-K: Report of foreign private issuer (related to financial reporting)

SEC announcement ·  Jan 31 07:03
Summary by Moomoo AI
Novo Nordisk A/S, a leading global healthcare company, reported a significant increase in financial performance for the period from January 1, 2023, to December 31, 2023. The company's sales surged by 31% in Danish kroner and 36% at constant exchange rates (CER), reaching DKK 232.3 billion. The operating profit followed suit, with a 37% increase in Danish kroner and a 44% rise at CER, amounting to DKK 102.6 billion. North America Operations saw a remarkable 50% growth in sales, while International Operations experienced an 11% increase. The Diabetes and Obesity care segment was a major contributor to this growth, with sales rising by 38% to DKK 215.1 billion, driven by GLP-1 diabetes sales and a staggering 147% increase in Obesity care sales. However, Rare disease sales saw a decrease of 16%. Novo Nordisk also...Show More
Novo Nordisk A/S, a leading global healthcare company, reported a significant increase in financial performance for the period from January 1, 2023, to December 31, 2023. The company's sales surged by 31% in Danish kroner and 36% at constant exchange rates (CER), reaching DKK 232.3 billion. The operating profit followed suit, with a 37% increase in Danish kroner and a 44% rise at CER, amounting to DKK 102.6 billion. North America Operations saw a remarkable 50% growth in sales, while International Operations experienced an 11% increase. The Diabetes and Obesity care segment was a major contributor to this growth, with sales rising by 38% to DKK 215.1 billion, driven by GLP-1 diabetes sales and a staggering 147% increase in Obesity care sales. However, Rare disease sales saw a decrease of 16%. Novo Nordisk also completed significant clinical trials, including the first phase 3a trial with IcoSema and a phase 1 trial with oral amycretin. Looking ahead to 2024, the company anticipates sales growth of 18-26% at CER and operating profit growth of 21-29% at CER. The Board of Directors plans to propose a final dividend of DKK 6.40 per share for 2023 at the Annual General Meeting on March 21, 2024, and has initiated a new share repurchase programme of up to DKK 20 billion.

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more